The study emphasized the positive response of MET-overexpressed TKI-naïve EGFR-mutant NSCLC cells to REGN5093-M114 treatment, suggesting its capability to complement EGFR TKIs in scenarios where they may fall short. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.